Pear Therapeutics, Inc.

Thimble Point Acquisition Corp, trading under the ticker THMA, is a blank-check company that completed its initial public offering in 2021 and is sponsored by Thimble Point LLC, a healthcare-focused sponsor. The SPAC targeted the digital health and therapeutics sector and announced a business combination with Pear Therapeutics, Inc., a developer of prescription digital therapeutics for conditions including substance use disorder and insomnia. The 8-K filed on November 23, 2021, under accession number 0001193125-21-338645, was submitted in connection with the pending merger transaction. The business combination subsequently closed in December 2021, taking Pear Therapeutics public. Visit SpacDesk and sign up for full data, filings history, and deal analytics on THMA and hundreds of other SPAC transactions.